Fulgent Genetics, INC Form 4 insider transactions

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc., reported a transaction in 2,087 shares of common stock on September 1, 2026.

Ming Hsieh, Chief Executive Officer, a Director and 10% owner of Fulgent Genetics, Inc., reported a transaction in 4,392 shares of common stock on September 1, 2026.

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc., sold 1,673 shares of common stock on September 2, 2026 for $19.66 per share.

Jian Xie, President and COO of Fulgent Genetics, Inc., sold 2,127 shares of common stock on September 2, 2026 for $19.66 per share.

Ming Hsieh, Chief Executive Officer, a Director and 10% owner of Fulgent Genetics, Inc., reported a transaction in 2,949 shares of common stock on August 26, 2026.

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc., reported a transaction in 1,168 shares of common stock on August 26, 2026.

Jian Xie, President and COO of Fulgent Genetics, Inc., sold 1,193 shares of common stock on August 27, 2026 for $19.91 per share.

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc., sold 939 shares of common stock on August 27, 2026 for $19.91 per share.

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc., reported a transaction in 2,747 shares of common stock on July 26, 2026.

Jian Xie, President and COO of Fulgent Genetics, Inc., reported a transaction in 4,361 shares of common stock on July 26, 2026.

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc., reported a transaction in 1,645 shares of common stock on July 26, 2026.

Fulgent Genetics President and COO Xie Jian sold 2,146 shares of common stock to cover tax obligations related to RSU vesting.

CFO Paul Kim disposed of 2,087 shares of Fulgent Genetics common stock to satisfy tax obligations related to RSU vesting.

Chief Scientific Officer Hanlin Gao sold 1,688 shares of Fulgent Genetics to cover tax obligations related to RSU vesting.

CEO Ming Hsieh reported the withholding of 4,392 shares of Fulgent Genetics common stock to satisfy tax obligations related to RSU vesting.

Fulgent Genetics President and COO Jian Xie sold 1,201 shares of common stock to satisfy tax withholding obligations related to restricted stock unit vesting.

CFO Paul Kim reported the withholding of 1,168 shares of Fulgent Genetics common stock to satisfy tax obligations related to restricted stock unit vesting.

Chief Scientific Officer Hanlin Gao sold 945 shares of Fulgent Genetics to cover tax obligations related to RSU vesting.

CEO Ming Hsieh reported the withholding of 2,949 shares of Fulgent Genetics common stock to satisfy tax obligations related to restricted stock unit vesting.

Director Michael Nohaile acquired 5,558 restricted stock units and 8,426 stock options as part of an equity compensation package.

Director Linda Dong was granted 11,117 restricted stock units in Fulgent Genetics, Inc. as part of an equity compensation plan.

Director Regina E. Groves was granted 11,117 restricted stock units in Fulgent Genetics, Inc. as part of a standard equity compensation plan.

Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a transaction involving the withholding of 1,645 shares to cover tax obligations upon the vesting of restricted stock units.

Fulgent Genetics President and COO Jian Xie reported a transaction involving the withholding of shares to cover tax obligations related to vested restricted stock units.

Fulgent Genetics CFO and Treasurer, Paul Kim, acquired 2,747 shares of common stock on April 26, 2026, through a tax withholding transaction.

Fulgent Genetics CEO Ming Hsieh amended a Form 4 filing to include The Ming Hsieh Trust and detail the cancellation of a prepaid variable forward agreement involving 750,000 shares.

Fulgent Genetics' President and COO, Jian Xie, reported the disposition of shares to cover tax obligations arising from restricted stock unit vestings.

Fulgent Genetics CFO Paul Kim disposed of shares to cover tax liabilities arising from the vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, reported the disposition of common stock shares to cover tax withholding obligations related to vested restricted stock units.

Fulgent Genetics CEO Ming Hsieh reported the disposition of shares to cover tax obligations related to restricted stock unit vestings.